Latest Blog Posts Tagged "Dyskinesia"
April 26, 2017
This week, Adamas Pharmaceuticals announced new data for a dyskinesia drug -- an extended-release formulation of amantadine designed to be taken once daily at bedtime.
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
January 10, 2017
The FDA recently agreed to review the New Drug Application for a dyskinesia medication developed by Adamas Pharmaceuticals.
October 31, 2016
A new drug for levodopa-induced dyskinesia is one step closer to potentially reaching market.
September 21, 2016
A new formulation of amantadine to better treat levodopa-induced dyskinesia is entering the home stretch.
June 14, 2016
Last September, Kimberly Spletter became one of the first U.S. patients to receive focused ultrasound treatment for dyskinesia with Parkinson's disease.
January 18, 2016
In our latest podcast, Christopher Bishop, PhD, discusses what may cause involuntary movements called dyskinesia with long-term Parkinson's disease and medication use.
December 28, 2015
Adamas has announced positive Phase III results for its treatment for dyskinesia, involuntary movements that are a side effect of levodopa use. Such a therapy could impact how we treat motor symptoms.
September 24, 2015
MJFF-funded researchers announced the first U.S. patients have received focused ultrasound for dyskinesia with PD, providing more information about this alternative approach to managing disease.
March 29, 2015
Rytary, an extended-release formuation of levodopa/carbidopa, will soon be available for prescription. The treatment requires more pills but comes with less dyskinesia.